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Aim: To identify lifestyle factors affecting risk of relapse.
Methods: A comparison of 131 relapsed melanoma patients with 147 non-relapsers.
Results: Relapsers were more likely to report financial hardship using a number of different
measures including access to holidays and feeling financially insecure (odds ratio (OR) 5.7,
95% confidence interval (CI) (1.5, 21.4)). Relapsers worked longer hours (mean 37 h per week
compared with 31, p = 0.02). There was no reported difference in stress associated with
recent life events. There was no effect of housing quality, employment factors or body mass
index (BMI) on risk of relapse. There was a protective effect of antibiotics in the peri-oper-
ative period.
Conclusion: The study provides preliminary evidence for adverse effects of chronic financial
hardship, but not recent stressful events on cancer relapse. As these data were collected in
a retrospective case–control study subject to recall bias, the data must now be explored in a
prospective study.
 2008 Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction higher socioeconomic status (hazard ratio 0.88 95% confi-Known predictors of survival in melanoma relate to charac-
teristics of the tumour such as the Breslow thickness, mitotic
rate and the presence of regression.1 There are also host fac-
tors which correlate with risk, such as the tumour site and the
patient’s sex.2 Little is known of other determinants of out-
come, except that whilst melanoma is more common in those
of high socioeconomic status, poorer survival is associated
with deprivation.3–5 A large study of older melanoma patients
recently showed a lower risk of death from melanoma withResearch UK in the for
ntre at Leeds. The study
Recruitment to the study
; fax: +44 113 234 0183.
ac.uk (J.A. Newton-Bisho
 CC BY-NC-ND license.dence interval (CI) (0.79, 0.98), p = 0.02) after adjusting for
sex, age, stage at diagnosis, thickness, site, co-morbidity in-
dex and histology,6 suggesting that poorer outcome in those
of lower socioeconomic status was not caused by measurable
diagnostic delay. Studying lifestyle in melanoma patients may
give further insight into the components of deprivation
affecting survival from cancer.
Melanoma is an immunogenic tumour: in that tumour
infiltrating lymphocytes are usual in primaries, and absence
of this immunological response to the tumour is a poor prog-m of programme grant C588/A4994 to the Genetic Epidemiology
was also funded by a grant from the Skin Cancer Research Fund
was supported by the National Cancer Research Network (NCRN).
p).
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sentinel node biopsy.7 The importance of immuno-compe-
tence to patients who have had melanoma was vividly illus-
trated by a case report in which two recipients of
transplanted kidneys developed melanoma derived from the
kidneys of the donor who had had melanoma 13 years previ-
ously.8 Furthermore, rare spontaneous or chemotherapy-re-
lated remissions may occur in the context of immune-
mediated vitiligo, when detectable immune responses to tu-
mour antigens may be demonstrable.9,10 Angiogenesis is also
critical for the development of metastatic disease.11,12 It is our
hypothesis that lifestyle or life events associated with depri-
vation may influence survival by modulation of immune re-
sponses to the tumour or by effects on angiogenesis. That
psychological stress might adversely affect host/tumour
interactions has been postulated for some time but it has
proved difficult to establish the validity of the hypothesis,
not least because of the difficulty of measuring immunologi-
cal changes in man which might mediate these effects. There
are, however, some psychosocial data which provide evidence
that stressful events and psychological distress may increase
the risk of relapse in cancer, and here we reference two of the
most recent.13,14 Some human studies have reported that
measurable changes in the immune system are associated
with quality of life after cancer supporting the view that qual-
ity of life and competence of the immune system are linked.15
There are also some data linking exposure to ‘stressors’ in
animal studies which have been adopted because of the diffi-
culties of designing human experiments focussed on vari-
ables which are complex and inter-related. So, recent
murine models have looked at such things as pharmacologi-
cal and physical stressors and promotion of metastases, and
the effect of rehousing (social stress) on the effectiveness of
chemotherapy16,17 and reported evidence that at least in lab-
oratory animals physical and social stress did appear to im-
pact on host/tumour interaction.
In this hypothesis generating study, we also explored a
number of additional different factors for which there was
limited supportive evidence in the literature for an effect on
relapse in order to inform the design of subsequent cohort
studies. We, therefore, looked at body mass index (BMI) which
has been reported to be associated with risk of melanoma18
and exposure to incidental drugs such as statins19and
L-Dopa.20
We designed a retrospective study of melanoma patients
in the UK to identify candidate lifestyle factors having an ef-
fect on relapse. We postulated that, by interviewing mela-
noma patients who relapsed late from melanoma and
patients who had not relapsed, we would identify relevant life
events having an effect on host/tumour interaction and,
therefore, relapse, occurring in the preceding years. This is
a hypothesis generating study, which was, therefore, by in-
tent one which has tested a large number of hypotheses.
2. Materials and methods
2.1. Patient recruitment
Recruitment took place between May 2000 and January 2005
from the Northern and Yorkshire, West Midlands, Oxfordand Trent regions of the UK. Approval was obtained from re-
gional and local ethics committees and the Patient Informa-
tion Advisory Group (PIAG). Eligible patients (‘relapsers’ and
‘non-relapsers’) were recruited from the clinics of participat-
ing clinicians. The ‘relapsers’ were patients aged over 18 years
at the time of recruitment with a melanoma >0.75 mm in
thickness, who had suffered a relapse from that melanoma
more than 3 years after removal of the primary tumour.
‘Non-relapsers’ were patients with a Breslow thickness
>0.75 mm who had not relapsed at 5 or more years. In order
to recruit long-term survivors who had been discharged from
follow-up, we also identified eligible non-relapsers treated by
the same doctors as the relapsers, using data from the cancer
registries. Relapsers and non-relapsers were frequency-
matched for age, sex and Breslow thickness.
The diagnostic histology sections from the primary tu-
mours were examined (blind to case/control status) by AB,
according to protocol. The following were recorded: Breslow
thickness, tumour type, presence of ulceration, regression,
mitotic rate, presence of tumour infiltrating lymphocytes
(TILs) and excision margins. Regression was defined as the
presence of scarring fibrosis, increased vascularity, a lympho-
cytic infiltrate and accumulation of melanophages.
2.2. Questionnaire data collection
Exposure data were collected using a specifically designed
questionnaire, and the Hospital Anxiety & Depression Scale
(HAD).21 The HAD questionnaire was used as a measure of
current psychological status. The new questionnaire was de-
signed in order to collect specific information relating to
deprivation, which was not necessarily identified using mea-
sures such as the Townsend score based upon postcode, or
was related to perceptions of deprivation. Therefore detailed
questions, for example, were asked about the participant’s
working life relating to whether the participants worked in
shifts, how many hours per week they worked, and whether
they found work stressful. Questions were asked about hous-
ing: relating to whether the participants felt that they had en-
ough room in the house for their family, whether they felt
that they had good neighbours and whether they felt safe at
home. Participants were asked whether they had adequate
access to recreational time at home or on holiday, and they
were also asked to list hobbies or other pleasurable pursuits,
and to indicate how much pleasure (out of a maximum score
of 10) the most enjoyable activity gave them. Whilst pleasure
resulting from hobbies may reflect current status rather than
be related to long-term mental health, we were trying to test
the hypothesis that positive or satisfying pastimes might be
protective, just as chronic stress might be associated with
an increased risk of relapse. In order to assess risk associated
with stressful life events, participants were asked about life
events potentially associated with psychological distress in
the 5 years prior to interview such as serious illness in a loved
one, miscarriage, divorce, bereavement, robbery or imprison-
ment. Participants were also asked to rank how the ‘event’
made them feel, from excellent to devastating on a 10-point
scale. Some events might at first appear to be stressful such
as a bereavement, but in some circumstances (for example,
where the deceased person was suffering prior to death) loss
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fore, attempted to measure the overall effect of his event
using the scale.
Financial difficulties were assessed by asking questions
about debts, redundancy and difficulties paying off loans.
We also asked the participants whether they perceived that
they were financially insecure, whether they felt able to take
holidays as they wished and whether they felt they struggled
to manage on their income and to pay for their car transport.
Data on alcohol intake and a brief smoking history
were recorded. Self-reported height and weight were used to
calculate a body mass index (BMI). We also used two post-
code-based systems to give a measure of deprivation: the
Townsend score22 and the ACORN system (ACORN@CACI
limited 2006).
Wound infections have been associated with increased
risk of relapse for some cancers such as colon cancer23 and
therefore, data were collected on wound healing after exci-
sion of the primary, reported wound infections and the use
of antibiotics around the time of surgery. In order to investi-
gate the possibility that exposures might modulate the
immune responses to cancer cells we asked about immunisa-
tion, blood transfusion and drug use. To investigate the
effects of genetic variation in immune responses, we also
asked the participants about their history of atopy or auto-
immune disease.Table 1 – A case–control comparison of postcode-derived afflue
Depression Scale (HAD) anxiety and depression scores, psych
Sexa
Female N (%)
Male
Agea
Years Mean (standard deviation, s.d.)
Breslowa
mm Median (range)
Townsend
Score Mean (s.d.)
Acorn
Wealthy achievers N (%)
Urban prosperity
Comfortably off
Moderate means
Hard pressed
HAD anxietyb
Score Mean (s.d.)
HAD depressionb
Score Mean (s.d.)
Have you regularly smoked?b
Yes N (%)
Do you still smoke?b
Yes N (%)
a Not tested because frequency matching factor.
b Analysis restricted to the 104 relapsers who were interviewed within tWe enquired about the use of incidental drugs of any kind
except for occasional analgesia.
2.3. Statistical methodology
Two-sided t-tests were used for comparing continuous mea-
sures between relapsers and non-relapsers. Mann–Whitney
U tests were used for non-normally distributed continuous
measures. Spearman’s correlations were calculated to explore
relationships between non-normally distributed continuous
variables. Associations between categorical variables and re-
lapse status were tested for using chi-squared tests and logis-
tic regression models. The data were also analysed in this way
to compare the distribution of the variables in the cases who
had relapsed less than 6.5 years post diagnosis to the cases
who relapsed 6.5 or more years post diagnosis.
Multivariable logistic regression models were used to fur-
ther explore any associations by adjusting for histological
characteristics of the tumour and also age and sex. For some
risk factors, analysis was restricted to relapsers interviewed
within two years of relapse (80% of relapsers) to minimise
the possibility that subjects were actually reporting the
effects rather than the causes of relapse. All statistical analy-
ses were carried out using STATA version 9 (StataCorp. 2005.
Stata Statistical Software: Release 9. College Station, TX:
StataCorp LP).nce scores (Townsend and ACORN), the Hospital Anxiety &
osocial indices and smoking histories
Non-relapsers Relapsers p-Value
99 (67.4) 88 (67.2) –
48 (32.7) 43 (32.8)
50.3 (14.3) 48.1 (14.3) –
1.5 (0.8–13) 1.7 (0.8–20) –
0.3 (3.4) 0.3 (3.4) 1.0
49 (33.3) 43 (33.6) 0.9
14 (9.5) 15 (11.7)
68 (46.3) 54 (42.2)
11 (7.5) 10 (7.8)
5 (3.4) 6 (4.7)
6.4 (3.6) 6.9 (3.9) 0.3
3.2 (2.7) 3.6 (2.8) 0.2
58 (45.3) 45 (46.9) 0.8
16 (26.7) 14 (29.8) 0.7
wo years of relapse.
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factor with 30% frequency in non-relapsers, which doubles
the risk of late relapse at a significance level of 5%. The power
was reduced to 70% in analyses restricted to relapsers inter-
viewed within two years of relapse. Because of the multiple
hypotheses tested in this study, the nominal p-values quoted
should not be interpreted at face value. A Bonferroni correc-
tion is not appropriate because of the correlation between
many of the tests. Few results significant at the 0.5% level
(p < 0.005) would be expected by chance, so findings signifi-
cant at this level will be prioritised for confirmation in our
ongoing prospective study of melanoma patients.
3. Results
424 patients were eligible for the study, of which 66% (278)
participated. The participation rate was 79% in relapsers
and 60% in non-relapsers. The median Breslow thickness
was 1.6 mm (range 0.8–20) (Table 1). There was no effect of
age on participation, but there was an effect of sex: 33% of
participating relapsers were male compared with 59% of
non-participating relapsers (p = 0.005), and 33% of participat-
ing non-relapsers were male compared with 26% of non-par-Table 2 – Comparing the distributions of histological tumour c
relapsers
Non-relapsers N (%) Relapsers N (%)
Site of primary
Axial 48 (33.1) 47 (35.9)
Limb 97 (66.9) 84 (64.1)
Ulceration
No 112 (91.1) 85 (82.5)
Yes 11 (8.9) 18 (17.5)
Tumour infiltrating lymphocytes
None 6 (4.9) 5 (4.9)
Mild 59 (48.0) 59 (57.3)
Non-brisk 31 (25.2) 26 (25.2)
Brisk 27 (22.0) 13 (12.6)
Regression
No 91 (74.0) 75 (72.8)
Yes 32 (26.0) 28 (27.2)
Initial incisional biopsy
No 124 (85.5) 117 (90.7)
Yes 21 (14.5) 12 (9.3)
Vertical growth phase
No 10 (8.1) 3 (2.9)
Yes 113 (91.9) 100 (97.1)
Mitotic ratea
Mean (s.d.) 2.3 (3.4) 4.0 (5.9)
Vessel invasionb
No 121 (98.4) 97 (94.2)
Yes 2 (1.6) 6 (5.8)
p-Value from Pearson’s chi-squared test for independence unless otherw
The number of missing data points ranges between 2 and 52 due to lack
a Two-tailed t-test, mean and standard deviation reported.
b Fisher’s exact test.ticipating non-relapsers (p = 0.2). Participating relapsers were
marginally more affluent than non-participating (mean
Townsend scores 0.3 and 1.6, respectively, two-sided t-test,
p = 0.08) but there was no difference for non-relapsers.
3.1. Nature of the relapse in relapsers
The median time from diagnosis to interview for non-relaps-
ers was 8.0 years (range 5.0–31.7) and the median time to re-
lapse for the relapsers was 6.6 years (range 3.0–28.1). There
was no evidence of a relationship between Breslow thickness
and time to relapse (rank correlation coefficient 0.01, p = 0.9).
The median time to relapse did not differ by the site of pri-
mary (median 5.9 years, IQR (4.3–8.7) for axial tumours, med-
ian 6.9 years, IQR (4.5–11.3) for tumours on the limbs, p = 0.2
Mann–Whitney U test), although patients with tumours on
the limbs were more likely to relapse very late (33% after 10
years) than those with axial tumours (19%).
3.2. Histological findings
There was no difference in the site of the primary between
relapsers and non-relapsers (Table 2, p = 0.8), or in any otherharacteristics and tumour site between relapsers and non-
p-Value Relapsers excluding
systemic relapsers
p-Value
0.6 37 (31.9) 0.8
79 (68.1)
0.1 74 (82.2) 0.1
16 (17.8)
0.3 5 (5.6) 0.4
52 (57.8)
21 (23.3)
12 (13.3)
0.8 65 (72.2) 0.8
25 (27.8)
0.2 104 (90.4) 0.2
11 (9.6)
0.1 3 (3.3) 0.1
87 (96.7)
0.01 4.2 (6.2) 0.01
0.1 85 (94.4) 0.1
5 (5.6)
ise stated.
of histological information for some patients.
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in relapsers than in non-relapsers (4.0/mm2 compared with
2.3/mm2, two-sided t-test, p = 0.01). When restricting the
analysis to the loco-regional relapsers (N = 116), to investigate
possible variation according to the stage of disease, the re-
sults were unchanged. When all the histological criteria were
considered in a multivariable analysis, none of the histologi-
cal characteristics were significantly independently associ-
ated with relapse. Such is the importance of histological
features in prognosis in larger data sets, however, that posi-
tive associations were adjusted for site, presence of ulcera-
tion, vertical growth phase, mitotic rate and vessel invasion.
3.3. Deprivation scores
The relapsers and non-relapsers did not differ in the mean
postcode-derived deprivation score (Table 1). There was good
correlation between the Townsend scores and the ACORNTable 3 – Odds ratios and 95% confidence intervals for the effe
melanoma relapse
Non-relapsers N (%) Relap
Financially secure
Yes 71 (56.4) 46
Reasonably 52 (41.3) 34
No 3 (2.4) 11
Run a car
Yes 112 (89.6) 72
Yes but struggle 7 (5.6) 17
No 6 (4.8) 6
Struggle on income
Comfortable 66 (53.2) 36
Reasonable 43 (34.7) 33
Struggle 15 (12.1) 24
Ever made redundant
No 95 (76.0) 65
Yes 30 (24.0) 28
Work shifts
No 58 (79.5) 42
Yes 15 (20.5) 10
Earned more in past
No 47 (37.6) 27
Yes 78 (62.4) 65
Unpaid credit card
No 102 (80.3) 72
Yes 25 (19.7) 22
Mortgage payment difficulties
No 123 (97.6) 91
Struggle 3 (2.4) 3
Take holidays where and when want
Yes 86 (67.7) 52
Sometimes 35 (27.6) 23
No 6 (4.7) 21
Odds ratios and 95% confidence intervals from unadjusted analysis.
Analysis restricted to the 104 relapsers who were interviewed within tw
The ‘work shifts’ factor was ascertained for the 125 patients currently em
The number of non-missing responses for the other factors ranges betw
a Likelihood ratio chi-squared p-value.scores (Spearman’s correlation coefficient 0.5, p < 0.0001)
and the questionnaire-based deprivation measures (data not
shown).
3.4. Perceived financial hardship, housing and working
Relapsers were significantly more likely to report that they did
not feel ‘financially secure’, (OR = 5.7 for not secure versus se-
cure, 95% CI (1.5, 21.4)). This association was strongest in peo-
ple within the less affluent half of the population (using
median Townsend score of –0.49 as the cut-off, Town-
sendP –0.49 OR = 8.4, 95% CI (0.9, 76.7) for no versus yes
and Townsend < –0.49 OR = 4.3, 95% CI (0.8, 22.9) for no versus
yes). Relapsers were more likely to say that they struggle to
run a car for financial reasons (OR = 3.8, 95% CI (1.5, 9.6)).
Relapsers were marginally more likely to answer that they
struggle on their income (OR = 2.9, 95% CI (1.4, 6.3) for ‘strug-
gle’ versus ‘comfortable’). Relapsers were more likely to sayct of factors relating to perceived financial hardship on
sers N (%) Odds ratio (95% CI) p-Valuea
(50.6) 1.0 0.02
(37.4) 1.0 (0.6, 1.8)
(12.1) 5.7 (1.5, 21.4)
(75.8) 1.0 0.005
(17.9) 3.8 (1.5, 9.6)
(6.3) 1.6 (0.5, 5.0)
(38.7) 1.0 0.02
(35.5) 1.4 (0.8, 2.6)
(25.8) 2.9 (1.4, 6.3)
(69.9) 1.0 0.3
(30.1) 1.4 (0.7, 2.5)
(80.8) 1.0 0.9
(19.2) 0.9 (0.3, 2.4)
(29.4) 1.0 0.2
(70.7) 1.5 (0.8, 2.6)
(76.6) 1.0 0.5
(23.4) 1.2 (0.7, 2.4)
(96.8) 1.0 0.7
(3.2) 1.4 (0.3, 6.9)
(54.2) 1.0 0.001
(24.0) 1.1 (0.6, 2.0)
(21.9) 5.8 (2.2, 15.3)
o years of relapse.
ployed.
een 217 and 223.
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(OR = 5.8, 95% CI (2.2, 15.3) for ‘no’ versus ‘yes’). The relapsers
reported longer working hours than the non-relapsers (mean
37 h per week compared with 31 for the non-relapsers, two-
sided t-test, p = 0.02). These associations persisted when ad-
justed for histological criteria. The models shown in Table 3
were repeated adjusting for age, and sex but this did not af-
fect the results.
3.5. Anxiety, depression and life events
There was no difference in HAD scores between relapsers and
non-relapsers: the mean anxiety score for non-relapsers was
6.4 and that for relapsers was 6.9 (two-sided t-test, p = 0.3, Ta-
ble 1). Similarly, the mean depression score for non-relapsers
was 3.2 and for relapsers it was 3.6 (two-sided t-test, p = 0.2).Table 4 – Odds ratios and 95% confidence intervals for the effe
interactions on melanoma relapse
Non-relapsers N (%) Rela
Polio immunisationa
Never/>5 years ago 105 (90.5)
In the last 5 years 11 (9.5)
Flu immunisationa
Never/>5 years ago 69 (53.9)
In the last 5 years 59 (46.1)
Tetanus immunisationa
Never/>5 years ago 92 (73.6)
In the last 5 years 33 (26.4)
Yellow fever immunisationa
Never 112 (87.5)
Ever 16 (12.5)
Any immunisation in the last 5 yearsa,c
No 29 (25.0)
Yes 87 (75.0)
Use of any drugs after diagnosis
No 85 (57.8)
Yes 62 (42.2)
Use of statins
No 144 (98.0)
Yes 3 (2.0)
Any oestrogen
No 141 (95.9)
Yes 6 (4.1)
Wound healing problems after primary
No 115 (80.4)
Yes 28 (19.6)
Skin graft for primary
No 77 (60.2)
Yes 51 (39.8)
Antibiotics after surgery
No 109 (76.2)
Yes 34 (23.8)
Odds ratios and 95% confidence intervals from unadjusted analysis.
a Analysis restricted to the 104 relapsers who were interviewed within t
b Likelihood ratio chi-squared p-value.
c Based on immunisations against polio, flu, pneumonia, hepatitis A, heRelapsers were marginally less likely to have experienced a
serious illness in a loved one than the non-relapsers (27% and
38%, respectively, p = 0.1). Similarly, relapsers were less likely
to have lost a loved one compared with non-relapsers (24%
and 45%, respectively, p = 0.001) but there was no difference
between relapsers and non-relapsers in the emotional effect
this was reported to have on them (p = 0.3). There was no dif-
ference in other individual listed ‘significant’ life events.
Overall, 71% of non-relapsers had experienced one or more
adverse life-events compared with 58% of relapsers
(p = 0.03). There was, however, no difference in the overall
stress rating of these events in relapsers and non-relapsers.
The number of reported hobbies was highly variable: 11%
overall reported none, whilst 20% reported 15 different hob-
bies or pleasurable activities. There was no difference be-
tween relapsers and non-relapsers in the number ofct of exposures postulated to influence host/tumour
psers N (%) Odds ratio (95% CI) p-Valueb
76 (87.4) 1.0 0.5
11 (12.6) 1.4 (0.6, 3.4)
48 (60.8) 1.0 0.3
31 (39.2) 0.8 (0.4, 1.3)
76 (83.5) 1.0 0.1
15 (16.5) 0.6 (0.3, 1.1)
84 (87.5) 1.0 1.0
12 (12.5) 1.0 (0.4, 2.2)
26 (33.8) 1.0 0.2
51 (66.2) 0.7 (0.3, 1.2)
87 (66.4) 1.0 0.1
44 (33.6) 0.7 (0.4, 1.1)
123 (93.9) 1.0 0.1
8 (6.1) 3.1 (0.8, 12.0)
126 (96.2) 1.0 0.9
5 (3.8) 0.9 (0.3, 3.1)
99 (82.5) 1.0 0.7
21 (17.5) 0.9 (0.5, 1.6)
68 (58.1) 1.0 0.7
49 (41.9) 1.1 (0.7, 1.8)
108 (90.0) 1.0 0.003
12 (10.0) 0.4 (0.2, 0.7)
wo years of relapse.
patitis B, bacilli Calmette-Guerin (BCG), meningitis and tetanus.
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associated with those hobbies (two-sided t-test, p = 0.01).
There was a negative correlation between the number of re-
ported hobbies and the HAD depression score, so that the
more hobbies were reported the less depressed the score
(Spearman correlation coefficient –0.1, p = 0.06).
The mean BMI for relapsers was 25.4 compared with 25.7
for non-relapsers (two-sided t-test, p = 0.7). Relapsers and
non-relapsers did not differ in reported alcohol intake or
smoking history.
3.6. Factors potentially related to host–tumour interaction
2% of relapsers and 3% of non-relapsers reported having an
auto-immune-mediated disease post diagnosis of the primary
melanoma. 4% of relapsers reported any atopic disease post
diagnosis of the primary melanoma compared with 2% of
non-relapsers.
There was no difference between relapsers and non-
relapsers in their history of recent (within 5 years) immunisa-
tion against polio (13% and 10%, respectively), flu vaccine (39%
and 46%, Table 4), pneumonia (8% and 13%), hepatitis A (10%
and 9%) or hepatitis B (6% and 5%). There was a marginal dif-
ference for recent immunisation against tetanus: 17% of
relapsers had been immunised against tetanus within the
previous 5 years compared with 26% of non-relapsers. In the
5 years before recruitment, one participant had been immun-
ised against bacilli Calmette-Guerin (BCG) and none had been
immunised against meningitis. Overall, 66% of the relapsers
had had one or more vaccine in the 5 years before interview
compared with 75% of the non-relapsers.
42% of the relapsers had had a skin graft at the time of
excision of the primary, compared with 40% of the non-
relapsers. The relapsers reported a median time to heal the
graft of 21 days compared with 14 days in the non-relapsers
(Mann–Whitney U test, p = 0.1). Wound healing problems were
reported in 18% of relapsers and 20% of non-relapsers. Relaps-
ers were less likely to have been given antibiotics around the
time of excision of the primary: 10% of the relapsers had anti-
biotics compared with 24% of the non-relapsers (OR 0.4, 95%
CI (0.2, 0.7), p = 0.003). This association remained when cor-
recting for Breslow thickness of the primary tumour (adjusted
OR 0.3, 95% CI (0.2, 0.7)). Enquiry revealed that in some hospi-
tals, antibiotic prescription was used prophylactially after
some surgical procedures such as skin grafting.
34% of the relapsers had taken at least one incidental ther-
apeutic drug regularly post diagnosis of the primary mela-
noma compared with 42% of the non-relapsers. 6% of
relapsers had taken statins compared with 2% of the non-
relapsers. None of the participants had taken L-Dopa. There
was no difference in exposures to non-steroidal anti-inflam-
matory drugs (6% of the relapsers compared with 4% of the
non-relapsers) or to immuno-suppressant drugs (5% of both
relapsers and non-relapsers).
3.7. Time to relapse
To eliminate the possibility of heterogeneity between the
relapsers who relapsed very late after the primary melanoma
and those who relapsed soon after the primary melanoma,the relapsers were stratified by the median time to relapse
(6.5 years) and the distributions of the significant findings
above were compared between these two groups. None of
the potential risk factors found in this study significantly dif-
fered between those who relapsed less than 6.5 years post
diagnosis and those who relapsed 6.5 or more years post
diagnosis.4. Discussion
Deprivation has been reported to reduce survival rates from
melanoma3,6 as it has for many cancers.24,25 We found no sig-
nificant difference between late relapsers and non-relapsers
in terms of their postcode-derived deprivation score or in re-
ported material effects of deprivation such as reported poor
housing, obesity, smoking and alcohol abuse. Relapsers were,
however, more likely to report perceived financial hardship
than were non-relapsers. The consistency of reported finan-
cial difficulties, related to several aspects of paucity of re-
sources, and the lack of detected differences in other
aspects of lifestyle are of note. A lack of difference in HAD
score between relapsers and non-relapsers suggests that clin-
ical depression or anxiety did not explain these differences.
Relapsers reported that they were no more likely to have suf-
fered a fall in income which suggests that their perceptions
about finances did not reflect a recent loss of employment
as a result of the relapse. It remains possible, however, that
these observations reflect recall bias or a perception that
things might be harder in the future as a result of the relapse.
Although these findings are of note therefore, they cannot yet
be interpreted: rather they will now be addressed prospec-
tively in a cohort study.
We report a hypothesis generating study designed to iden-
tify possible environmental factors associated with relapse
from melanoma. We chose a case–control study design as a
reasonable approach to hypothesis generation, in order to in-
form the design of much more expensive cohort studies.
There are many problems, however, inherent in case–control
studies around bias of recall but in epidemiological studies
addressed to cancer aetiology, they have proved very effective
and generally speaking have identified risk factors validated
in subsequent cohort studies. In the melanoma field, for
example, case–control studies identified sun burn and sun
sensitive phenotypes as the key risk factors for melanoma26
as was confirmed in a Nordic cohort study.27 Thus a case–con-
trol study is a reasonable approach to the identification of
potentially important new exposures which may be causal
for or protective of relapse. One of the measures identified
by this study, however, was perceived financial hardship
and whilst this is potentially a real finding, psychosocial fac-
tors are likely to be especially subject to basis of recall and
therefore this finding must be viewed with some caution.
The means by which perceived financial hardship might
impact on survival is unknown but it is postulated to be med-
iated by stress-induced immune suppression.28,29 The Town-
send score uses census data on unemployment,
overcrowding, non-car ownership and non-home ownership,
based upon small enumeration districts to compute a ranked
score22 for material deprivation. It has been shown to be
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such as postoperative mortality22 for other cancers but in this
study did not predict case–control status. We matched for
Breslow thickness because it is a known predictor of survival,
but this could have removed some of the effect of socioeco-
nomic status in our study. Our observations may suggest that
direct questioning about material deprivation is more sensi-
tive than postcode-derived measures or that it is the percep-
tion of financial hardship that is the key predictor. Lack of
money and the impact that has on empowerment and psy-
chological stress may be more important than specific effects
on living conditions such as overcrowding. Although more
affluent patients were more likely to take part in the study
overall, proportionally fewer relapsers from deprived areas
took part than non-relapsers so that any recruitment bias is
likely to have reduced the size of the effect seen rather than
to increase it. Moreover, in this study we matched for Breslow
thickness at diagnosis to reduce the effect of any deprivation-
related treatment delay.
We postulated that recent stressful life events might in-
crease the risk of relapse from melanoma, but the study pro-
duced no support for a role for these in the late relapse. Our
study did provide support for the view that melanoma pa-
tients might be more subject to adverse effects from financial
stress (assumed to be chronic) than ‘recent significant’ life
events. It was postulated that psychological stress has a neg-
ative effect on survival from cancer as a result of immune
suppression as suggested by others,28,29 although this re-
mains a controversial concept. Studying immune changes
as a result of psychological changes is inherently difficult
and some researchers have used animal models to address
this. A recent study, for example, suggested that in mice, im-
mune suppression resultant from stress induced by restraint,
is mediated by toll-like receptor 430 and there are a number of
murine studies in which mice with components of the im-
mune system knocked out responded differently to stressors
that wild type mice.31 Whilst the issue remains under inves-
tigation, there are, therefore, data to support a relationship
between psychological stress and immune suppression and
as melanoma is an immunogenic tumour the possibility that
psychological stress in some form might have a deleterious
effect on survival remains a possibility. Furthermore, there
are data to support the view that chronic stress appears to re-
sult in suppression of the immune response, whereas both
immune activation and suppression have been associated
with acute stress.32,33 Our study provided little evidence for
a protective effect of support or hobbies but this will be better
addressed in a prospective study.
We further hypothesised that exposures which reduce
cell-mediated responses (such as smoking and immuno-sup-
pressant drugs) may be risk factors for relapse,34 but no evi-
dence for this was found in an albeit small study. There is
evidence that Th1-type immune responses are modulated in
life in response to immunisation and infection, and there
are data to support the view that these exposures, particularly
in early life, may influence the subsequent development of
diseases such as atopy.35 This prompted others working on
melanoma to explore the possibility that vaccination may
be protective for melanoma, and Pfahlberg and colleagues
showed that previous bacilli Calmette-Guerin (BCG) was pro-tective for melanoma risk.36 We found no evidence for a rela-
tionship between past medical history or immunisation and
risk of relapse. The study was, however, insufficiently pow-
ered to exclude significant relationships of this sort.
Wound healing is characterised by reduced cellular immu-
nity and new blood vessel formation, and delayed wound
healing results in chronic inflammation. The importance of
new blood vessel formation and chronic inflammation in
the promotion of cancer was reviewed by Dalgleish.37 The
apparent protective effect of antibiotics around excision of
the primary tumour in this study is of interest. It is possible
that the use of antibiotics might reduce an infection-related
drive to angiogenesis, although it is likely that this was a
chance finding. It will be addressed, however, in a prospective
study.
This study has identified some life-style factors, which
might be important as components of deprivation-related
moderation of survival. There was evidence that perceived
financial difficulty was related to risk of relapse, whereas
more acute adverse life events appeared not to be. There
was evidence to support the view that exposure to antibiotics
used at the time of surgery for primary melanoma was pro-
tective for relapse.
This was a hypothesis generating study. It was small and
retrospective and subject to multiple testing. The conclusions
drawn may therefore be subject to bias and must be explored
in larger prospective studies. The study does, however, pro-
vide a basis for those prospective investigations.
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